ReviewWorld journal of urology2005
Endothelin receptor antagonists.
Review in World journal of urology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 62 citations in OpenAlex.
- Potential New Treatments for Chronic Kidney Diseases: A Concise Review.Current pharmaceutical design · 2025Review
- Novel strategies in nephrology: what to expect from the future?Clinical kidney journal · 2023Review
- DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone Metastasis.Translational oncology · 2018Article
- Molecular Pathogenesis and Diagnostic Imaging of Metastatic Jaw Tumors.Journal of pharmacy & bioallied sciences · 2017Review
- Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.Molecular carcinogenesis · 2009Article
- Tumor-evoked sensitization of C nociceptors: a role for endothelin.Journal of neurophysiology · 2008Article
- Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.World journal of urology · 2007Review
- Clinical trials in metastatic hormone-refractory prostate cancer: improving docetaxel therapy by targeting bone-related growth factors.Current oncology reports · 2007Article
- Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.Molecular endocrinology (Baltimore, Md.) · 2007Article
- Tumor metastasis to bone.Arthritis research & therapy · 2007Review
- Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1.BMC musculoskeletal disorders · 2006Article
- Endothelin receptor A blockade enhances taxane effects in prostate cancer.Neoplasia (New York, N.Y.) · 2006Article
- Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.British journal of pharmacology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression. New targets and new therapies are demanded. Through a review of the available literature on endothelin and several preclinical observations, the endothelin axis has emerged as one such target. In phase II and III clinical trials of atrasentan, a potent and selective endothelin receptor A subtype (ET(A)) antagonist, disease progression was delayed in some men. This well tolerated, oral agent may help convert advanced prostate cancer to a more chronic disease. This review will discuss the endothelin axis, preclinical rationale and some of the available clinical trial data on this promising new approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.